REDUCE-IT Analysis Outlines Benefit of Icosapent Ethyl Across Range of LDL-C Levels
A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.
Linkedin Rahul Aggarwal Rahul Aggarwal Office Of The Commissioner Harvard Medical School Drug Administration American College Of Cardiology
Source: hcplive.com